In addition, our flow cytometry results suggest that ex vivo evaluation of levels of cell surface CDCP1 in tumor biopsies or circulating malignant cells could also serve to stratify patients for CDCP1-targeted therapies. The gene discussed is CDCP1; the disease is neoplasm.